Evidence map›Paper›PMID 40676436›Full record

ArticleInternational journal of clinical oncology2025

Optimizing radiation therapy for merkel cell carcinoma: evaluating prognostic factors and treatment outcomes.

Minori Niwa, Masanari Niwa, Natsuo Tomita, Hiromichi Ishiyama, Ayaka Uchida, Yukihiko Oshima, Hirota Takano, Masayuki Matsuo, Mayu Kuno, Akifumi Miyakawa and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Minori NiwaDepartment of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Masanari NiwaDepartment of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan. masamasa.niwa@gmail.com.ORCID http://orcid.org/0000-0002-7718-5811
Natsuo TomitaDepartment of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Hiromichi IshiyamaDepartment of Radiation Oncology, Kitasato University Hospital, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0375, Japan.
Ayaka UchidaDepartment of Radiation Oncology, Kitasato University Hospital, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0375, Japan.
Yukihiko OshimaDepartment of Radiology, Aichi Medical University Hospital, 1-1 Yazako-Karimata, Nagakute, Aichi, 480-1195, Japan.
Hirota TakanoDepartment of Radiation Oncology, Gifu University Hospital, 1-1 Yanagido, Gifu, 500-1194, Japan.
Masayuki MatsuoDepartment of Radiation Oncology, Gifu University Hospital, 1-1 Yanagido, Gifu, 500-1194, Japan.
Mayu KunoDepartment of Radiation Oncology, Ichinomiya Municipal Hospital, 2-2-22, Bunkyo, Ichinomiya, Aichi, 491-8558, Japan.
Akifumi MiyakawaDepartment of Radiation Oncology, National Hospital Organization Nagoya Medical Center, 4-1-1, Sannomaru, Naka-ku, Nagoya, Aichi, 460-0001, Japan.
Shinya OtsukaDepartment of Radiology, Okazaki City Hospital, 3-1, Kouryuuji-cho Gosyoai, Okazaki, Aichi, 444-8553, Japan.
Toru MatsuiDepartment of Radiation Oncology, Konan Kosei Hospital, 137 Omatsubara, Takaya-cho, Konan, Aichi, 483-8704, Japan.
Shintaro YamamotoDepartment of Radiology, Chukyo Hospital, 1-1-10 Sanjyo, Minami-ku, Nagoya, Aichi, 457-8510, Japan.
Taiki TakaokaDepartment of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Dai OkazakiDepartment of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Akira ToriiDepartment of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Nozomi KitaDepartment of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Seiya TakanoDepartment of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Motoki NakamuraDepartment of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Hiroshi KatoDepartment of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Akimichi MoritaDepartment of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Akio HiwatashiDepartment of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMerkel cell carcinoma (MCC) is a highly aggressive neuroendocrine skin cancer. Surgery and radiation therapy (RT) are common treatment options; however, an optimal RT strategy has yet to be established. Therefore, the present study examined the outcomes of MCC patients treated with RT, with the aim of elucidating current RT practices and identifying prognostic factors for RT optimization.

methodsThis was a retrospective analysis of 32 non-metastatic MCC patients treated with RT. Local control (LC), progression-free survival (PFS), and overall survival (OS) rates were calculated using the Kaplan-Meier method. The Log-rank test was used to examine the effect of each factor on outcomes.

resultsMedian age was 80 years, with a median follow-up period of 26 months. The median dose was 52 Gy in 26 fractions and combined with surgery in 23 patients. Two-year LC, PFS, and OS rates were 94, 61, and 74%, respectively. The Log-rank test showed that tumor size ≥ 5 cm was associated with worse LC (p = 0.03). Male sex and the absence of surgery correlated with worse PFS (p = 0.047 and 0.023, respectively). Performance status ≥ 2, the absence of surgery, and RT margin < 3 cm correlated with worse OS (p = 0.006, 0.02, and 0.02, respectively). RT dose, intensity-modulated RT, and elective nodal irradiation were not associated with any outcomes in this population.

conclusionRT achieved high local control; however, the metastasis rates were high. A wide RT margin and the combination of RT with surgery may improve the outcomes of MCC patients.

Indexed as

Carcinoma, Merkel CellSkin NeoplasmsAgedAged, 80 and overFemaleHumansKaplan-Meier EstimateMaleMiddle AgedPrognosisProgression-Free SurvivalRetrospective StudiesTreatment OutcomeMerkel cell carcinomaprognostic factorsradiation therapy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.